Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Graph

CYPH Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $197.00K; Operating expenses $4.69M; Income tax $1.97M.
  • 2026-03-31: Revenue (m); Research and development $161.00K; Operating expenses $4.82M; Income tax -$5.12M.
  • 2025-12-31: Revenue (m); Research and development $975.00K*; Operating expenses $5.10M*; Income tax $5.05M*.
  • 2025-09-30: Revenue (m); Research and development $1.25M; Operating expenses $3.17M; Income tax $202.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$197.00K$4.69M$1.97M$39.39M
2026-03-31(m)$161.00K$4.82M-$5.12M-$77.17M
2025-12-31(m)$975.00K*$5.10M*$5.05M*$40.38M*
2025-09-30(m)$1.25M$3.17M$202.00K-$3.30M
2025-06-30(m)$10.54M$16.88M(m)-$16.64M
2025-03-31(m)$12.91M$15.92M(m)-$15.44M
2024-09-30(m)$14.91M$17.86M$708.00K-$18.18M
2024-06-30(m)$17.89M$21.25M(m)-$20.13M
2024-03-31(m)$11.30M$14.82M(m)-$13.82M
2023-09-30(m)$11.50M$14.83M(m)-$13.70M
2023-06-30(m)$11.10M$14.66M(m)-$13.39M
2023-03-31(m)$38.94M$42.73M(m)-$41.86M
2022-09-30(m)$12.10M$15.29M(m)-$15.09M
2022-06-30(m)$14.04M$16.90M(m)-$17.02M
2022-03-31(m)$7.78M$10.63M(m)-$10.38M
2021-09-30$375.00K$10.08M$12.52M(m)-$11.14M
2021-06-30$375.00K$7.21M$10.00M(m)-$9.53M
2021-03-31$375.00K$6.81M$9.55M(m)-$9.13M
2020-09-30$375.00K$5.37M$7.88M(m)-$7.06M
2020-06-30$375.00K$5.35M$7.87M(m)-$6.52M
2020-03-31$375.00K$4.60M$6.76M(m)-$7.23M
2019-09-30(m)$5.77M$7.92M(m)-$7.93M
2019-06-30(m)$6.14M$8.46M(m)-$8.37M
2019-03-31(m)$6.79M$8.79M(m)-$8.60M
2018-09-30(m)$6.46M$8.60M(m)-$6.63M
2018-06-30(m)$4.23M$6.84M(m)-$7.36M
2018-03-31(m)$4.23M$6.34M(m)-$10.62M
2017-09-30(m)$6.80M$8.58M(m)-$6.82M
2017-06-30(m)$4.88M$7.02M(m)-$6.91M
2017-03-31(m)$6.40M$10.21M(m)-$9.41M
2016-09-30(m)$5.66M$7.03M(m)-$7.28M
2016-06-30(m)$6.12M$7.19M(m)-$7.48M
2016-03-31(m)$4.09M$5.14M(m)-$5.15M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$358.00K$9.51M-$3.15M-$37.78M
2025-06-30(m)$23.45M$32.80M(m)-$32.08M
2024-06-30(m)$29.18M$36.08M(m)-$33.95M
2023-06-30(m)$50.05M$57.39M(m)-$55.25M
2022-06-30(m)$21.83M$27.53M(m)-$27.40M
2021-06-30$750.00K$14.01M$19.55M(m)-$18.66M
2020-06-30$750.00K$9.95M$14.63M(m)-$13.75M
2019-06-30(m)$12.93M$17.26M(m)-$16.97M
2018-06-30(m)$8.46M$13.18M(m)-$17.99M
2017-06-30(m)$11.29M$17.22M(m)-$16.32M
2016-06-30(m)$10.21M$12.34M(m)-$12.62M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$24.70M$35.96M$202.00K-$35.38M
2024-09-30(m)$44.10M$53.93M$708.00K-$52.12M
2023-09-30(m)$61.55M$72.22M(m)-$68.95M
2022-09-30(m)$33.93M$42.82M(m)-$42.49M
2021-09-30$1.13M$24.09M$32.06M(m)-$29.80M
2020-09-30$1.13M$15.32M$22.51M(m)-$20.80M
2019-09-30(m)$18.70M$25.18M(m)-$24.90M
2018-09-30(m)$14.92M$21.78M(m)-$24.62M
2017-09-30(m)$18.09M$25.81M(m)-$23.13M
2016-09-30(m)$15.87M$19.36M(m)-$19.90M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$25.67M$41.07M$5.25M$5.00M
2024-12-31(m)$57.21M$70.06M$585.00K-$68.00M
2023-12-31(m)$73.23M$87.04M(m)-$81.00M
2022-12-31(m)$44.97M$56.76M$147.00K-$54.60M
2021-12-31$1.50M$32.16M$42.93M-$24.00K-$40.59M
2020-12-31$1.50M$20.42M$30.04M-$2.00K-$27.51M
2019-12-31(m)$24.37M$33.45M-$3.00K-$32.90M
2018-12-31(m)$21.83M$30.75M$20.00K-$23.14M
2017-12-31(m)$22.50M$32.35M-$157.00K-$29.73M
2016-12-31(m)$23.29M$27.30M(m)-$25.63M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06